1-6 of 6
Patricia Roxburgh
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1620: Vulnerability to selective CTPS1 inhibition in cancers lacking CTPS2

Free
Philip A. Beer, John P. Thomson, Charlie Gourley, Alison Meynert, Andrew E. Parker, Brian Schwartz, Patricia Roxburgh
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 1620.
https://doi.org/10.1158/1538-7445.AM2025-1620
Published: 21 April 2025
View articletitled, Abstract 1620: Vulnerability to selective CTPS1 inhibition in cancers lacking CTPS2
Journal Articles

Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin

Open Access
Gwo Yaw Ho, Elizabeth L. Kyran, Justin Bedo, Matthew J. Wakefield, Darren P. Ennis, Hasan B. Mirza, Cassandra J. Vandenberg, Elizabeth Lieschke, Andrew Farrell, Anthony Hadla, Ratana Lim, Genevieve Dall, James E. Vince, Ngee Kiat Chua, Olga Kondrashova, Rosanna Upstill-Goddard, Ulla-Maja Bailey, Suzanne Dowson, Patricia Roxburgh, Rosalind M. Glasspool, Gareth Bryson, Andrew V. Biankin, for the Scottish Genomes Partnership, Susanna L. Cooke, Gayanie Ratnayake, Orla McNally, Nadia Traficante, for the Australian Ovarian Cancer Study12,13, Anna DeFazio, S. John Weroha, David D. Bowtell, Iain A. McNeish, Anthony T. Papenfuss, Clare L. Scott, Holly E. Barker
Journal: Cancer Research
Cancer Res (2022) 82 (23): 4457–4473.
https://doi.org/10.1158/0008-5472.CAN-21-4012
Published: 02 December 2022
View articletitled, Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
Open the PDF for Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin in another window
Includes: Supplementary data
Journal Articles

Abstract CT202: Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble lag-3 protein) and pembrolizumab

Free
Martin Forster, Enriqueta Felip, Bernhard Doger, Margarita Majem, Enric Carcereny, Julio Peguero, Pawan Bajaj, Tim Clay, Matthew Krebs, Patricia Roxburgh, Leora Horn, Frederic Triebel
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT202.
https://doi.org/10.1158/1538-7445.AM2020-CT202
Published: 15 August 2020
View articletitled, Abstract CT202: Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble lag-3 protein) and pembrolizumab
Journal Articles

Abstract 749: Multi-layer molecular characterization of high grade serous ovarian carcinomas

Free
Robert L. Hollis, Alison M. Meynert, Michael Churchman, Tzyvia Rye, Patricia Roxburgh, Daniel Stetson, Athena Matakidou, Brian Dougherty, J. Carl Barrett, Ruth E. March, Colin A. Semple, C. Simon Herrington, Charlie Gourley
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 749.
https://doi.org/10.1158/1538-7445.AM2019-749
Published: 01 July 2019
View articletitled, Abstract 749: Multi-layer molecular characterization of high grade serous ovarian carcinomas
Journal Articles

Abstract CT027: Safety, pharmacokinetics (PK) & pharmacodynamics (PD) of idasanutlin (idasa), combined with abiraterone (abi)/prednisolone (pred) or enzalutamide (enza) in castrate resistant prostate cancer (CRPC)

Free
Patricia Roxburgh, Dawn Currie, Paula Morrison, Caroline Kelly, Fiona Thomson, Carol McCormick, Alan Bilsland, Robert H. Jones, Amy Quinton, Elaine McCartney, Lorraine Barwell, Rob J. Jones
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT027.
https://doi.org/10.1158/1538-7445.AM2018-CT027
Published: 01 July 2018
View articletitled, Abstract CT027: Safety, pharmacokinetics (PK) & pharmacodynamics (PD) of idasanutlin (idasa), combined with abiraterone (abi)/prednisolone (pred) or enzalutamide (enza) in castrate resistant prostate cancer (CRPC)
Journal Articles

Abstract SY29-01: Functions of wild type and mutant p53

Free
Patricia Muller, Patricia Roxburgh, Patrick Caswell, Jim Norman, Karen H. Vousden
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): SY29-01.
https://doi.org/10.1158/1538-7445.AM10-SY29-01
Published: 15 April 2010
View articletitled, Abstract SY29-01: Functions of wild type and mutant p53